ALK Fusion | Cancer Search

Details 59 Trials 23 Therapies

mutation class

Gene Rearrangement

synonyms

ALK+

ALK 融合

ALK(+)

ALK+ve

ALK-(+)

ALK-pos

ALK Positive

ALK-positive

ALK rearrangement

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

281 sites for NCT04824092

ALK Fusion, +4 more biomarkers

ALK-Positive Large B-Cell Lymphoma, +7 more conditions

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

104 sites for NCT04589845

AKT1 Mutation, +39 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +8 more drugs

immunotherapy, +1 more type

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

155 sites for NCT03178552

ALK Alternative Transcription Site, +7 more biomarkers

Non-Small Cell Lung Carcinoma

alectinib, +2 more drugs

immunotherapy, +1 more type

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

78 sites for NCT02693535

AKT1 Mutation, +128 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +19 more conditions

abemaciclib, +23 more drugs

immunotherapy, +1 more type

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

127 sites for NCT02568267

ALK Fusion, +4 more biomarkers

Malignant Solid Tumor

entrectinib

targeted therapy

Show 59 Trials for ALK Fusion

lorlatinib

ALK Fusion

Non-Small Cell Lung Carcinoma